Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

ClinicalTrials.gov ID: NCT01259492

Public ClinicalTrials.gov record NCT01259492. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy and Safety Study of Methylphenidate HCl Extended Release in the Treatment of Adult Patients With Childhood-onset ADHD

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate efficacy and safety of methylphenidate hydrochloride extended release compared to placebo in adult patients with childhood-onset attention deficit/hyperactivity disorder (ADHD).

Study identification

NCT ID
NCT01259492
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
725 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2010
Primary completion
Jul 31, 2012
Completion
Jul 31, 2012
Last update posted
Oct 6, 2014

2010 – 2012

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
19
Facility City State ZIP Site status
Novartis Investigative Site Little Rock Arkansas 72205
Novartis Investigative Site Beverly Hills California 90210
Novartis Investigative Site Spring Valley California 91978-1522
Novartis Investigative Site Bradenton Florida 34208
Novartis Investigative Site Miami Florida 33173
Novartis Investigative Site Orlando Florida 32806
Novartis Investigative Site West Plam Beach Florida 33407
Novartis Investigative Site Libertyville Illinois 60048
Novartis Investigative Site Owensboro Kentucky 42301
Novartis Investigative Site Troy Michigan 48083
Novartis Investigative Site Las Vegas Nevada 89119
Novartis Investigative Site Las Vegas Nevada 89128
Novartis Investigative Site Willingboro New Jersey 08046
Novartis Investigative Site Fargo North Dakota 58103
Novartis Investigative Site Columbus Ohio 43210
Novartis Investigative Site Oklahoma City Oklahoma 73112
Novartis Investigative Site Philadelphia Pennsylvania 19149
Novartis Investigative Site Houston Texas 77007
Novartis Investigative Site Houston Texas 77008
Novartis Investigative Site Bellevue Washington 98004
Novartis Investigative Site Seattle Washington 98104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01259492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 6, 2014 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01259492 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →